Data and delivery: Inside AI's inventorship dilemma
Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 April 2026 The maker of a cosmetic penile implant has suffered at the Federal Circuit, after a ruling said its trade secrets claims are not protectable while leaving a counterfeiting finding intact.
17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.